Considerations for management of migraine symptoms in the primary care setting

References

• World Health Organization. Online Q&A how common are headaches? 2014 [cited 2015 May 18]. Available from: http://www.who.int/features/qa/25/en/
   Google Scholar
• Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2163–2196.
   PubMed Web of Science ®Google Scholar
• World Health Organization and Lifting the Burden. Atlas of headache disorders and resources in the world; 2011 [cited 2015 May 11]. Available from: http://www.who.int/mental_health/management/atlas_headache_disorders/en/
   Google Scholar
• Smitherman TA, Burch R, Sheikh H, et al. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. Headache. 2013;53:427–436.
   PubMed Web of Science ®Google Scholar
• Burch RC, Loder S, Loder E, et al. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache. 2015;55:21–34.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343–349.
   PubMed Web of Science ®Google Scholar
• Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA. 1992;267:64–69.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American migraine study II. Headache. 2001;41:646–657.
   PubMed Web of Science ®Google Scholar
• Pressman A, Jacobson A, Eguilos R, et al. Prevalence of migraine in a diverse community-electronic methods for migraine ascertainment in a large integrated health plan. Cephalalgia. 2016;36:325–334.
   Web of Science ®Google Scholar
• Pavlović JM, Stewart WF, Bruce CA, et al. Burden of migraine related to menses: results from the AMPP study. J Headache Pain. 2015;16:24.
   PubMed Web of Science ®Google Scholar
• Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30:599–609.
   PubMed Web of Science ®Google Scholar
• Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52:1456–1470.
   PubMed Web of Science ®Google Scholar
• Blau JN. Migraine prodromes separated from the aura: complete migraine. Br Med J. 1980;281:658–660.
   PubMed Web of Science ®Google Scholar
• Giffin NJ, Ruggiero L, Lipton RB, et al. Premonitory symptoms in migraine: an electronic diary study. Neurology. 2003;60:935–940.
   PubMed Web of Science ®Google Scholar
• Kelman L. The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. Headache. 2004;44:865–872.
   PubMed Web of Science ®Google Scholar
• Quintela E, Castillo J, Muñoz P, et al. Premonitory and resolution symptoms in migraine: a prospective study in 100 unselected patients. Cephalalgia. 2006;26:1051–1060.
   PubMed Web of Science ®Google Scholar
• Pavlović JM, Buse DC, Sollars CM, et al. Trigger factors and premonitory features of migraine attacks: summary of studies. Headache. 2014;54:1670–1679.
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629–808.
   PubMed Web of Science ®Google Scholar
• Russell MB, Olesen J. A nosographic analysis of the migraine aura in a general population. Brain. 1996;119:355–361.
   PubMed Web of Science ®Google Scholar
• Dodick D, Silberstein S. Migraine. New York: Oxford University Press; 2016.
   Google Scholar
• Fine EJ. The Alice in Wonderland syndrome. Prog Brain Res. 2013;206:143–156.
   PubMed Web of Science ®Google Scholar
• Ilik F, Ilik K. Alice in Wonderland syndrome as aura of migraine. Neurocase. 2014;20:474–475.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Buse DC, Saiers J, et al. Frequency and burden of headache-related nausea: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2013;53:93–103.
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Migraine symptoms: results of a survey of self-reported migraineurs. Headache. 1995;35:387–396.
   PubMed Web of Science ®Google Scholar
• Rasmussen BK, Jensen R, Olesen J. A population-based analysis of the diagnostic criteria of the International Headache Society. Cephalalgia. 1991;11:129–134.
   PubMed Web of Science ®Google Scholar
• Olesen J. Some clinical features of the acute migraine attack. An analysis of 750 patients. Headache. 1978;18:268–271.
   PubMed Web of Science ®Google Scholar
• Selby G, Lance JW. Observations on 500 cases of migraine and allied vascular headache. J Neurol Neurosurg Psychiatry. 1960;23:23–32.
   PubMed Web of Science ®Google Scholar
• Drummond PD. A quantitative assessment of photophobia in migraine and tension headache. Headache. 1986;26:465–469.
   PubMed Web of Science ®Google Scholar
• Kelman L. The postdrome of the acute migraine attack. Cephalalgia. 2006;26:214–220.
   PubMed Web of Science ®Google Scholar
• Giffin NJ, Lipton RB, Silberstein SD, et al. The migraine postdrome. An electronic diary study. Neurology. In Press.
   Google Scholar
• Stokes M, Becker WJ, Lipton RB, et al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS). Headache. 2011;51:1058–1077.
   PubMed Web of Science ®Google Scholar
• Munakata J, Hazard E, Serrano D, et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2009;49:498–508.
   PubMed Web of Science ®Google Scholar
• Hawkins K, Wang S, Rupnow MF. Indirect cost burden of migraine in the United States. J Occup Environ Med. 2007;49:368–374.
   PubMed Web of Science ®Google Scholar
• Hawkins K, Wang S, Rupnow M. Direct cost burden among insured US employees with migraine. Headache. 2008;48:553–563.
   PubMed Web of Science ®Google Scholar
• Berra E, Sances G, De Icco R, et al. Cost of chronic and episodic migraine. A pilot study from a tertiary headache centre in northern Italy. J Headache Pain. 2015;16:532.
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Stovner LJ, Katsarava Z, et al. The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain. 2014;15:31.
   PubMed Web of Science ®Google Scholar
• Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24(Suppl. 1):9–160.
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2010;31:301–315.
   PubMed Web of Science ®Google Scholar
• Buse D, Dodick D, Manack A. Perception of the family burden of chronic migraine: results of the CaMEO (Chronic Migraine Epidemiology & Outcomes) study. Neurology. 2015;84(14 Suppl):P5.039.
   Google Scholar
• Latinovic R, Gulliford M, Ridsdale L. Headache and migraine in primary care: consultation, prescription, and referral rates in a large population. J Neurol Neurosurg Psychiatry. 2006;77:385–387.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Scher AI, Steiner TJ, et al. Patterns of health care utilization for migraine in England and in the United States. Neurology. 2003;60:441–448.
   PubMed Web of Science ®Google Scholar
• Minen MT, Loder E, Tishler L, et al. Migraine diagnosis and treatment: a knowledge and needs assessment among primary care providers. Cephalalgia. 2016;36:358–370.
   PubMed Web of Science ®Google Scholar
• Bösner S, Hartel S, Diederich J, et al. Diagnosing headache in primary care: a qualitative study of GPs’ approaches. Br J Gen Pract. 2014;64:e532–e537.
   Google Scholar
• Bernstein JA, Fox RW, Martin VT, et al. Headache and facial pain: differential diagnosis and treatment. J Allergy Clin Immunol Pract. 2013;1:242–251.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Lipton RB, Dodick DW. Operational diagnostic criteria for chronic migraine: expert opinion. Headache. 2014;54:1258–1266.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Serrano D, Buse DC, et al. Improving the detection of chronic migraine: development and validation of identify chronic migraine (ID-CM). Cephalalgia. 2016;36:203–215.
   Web of Science ®Google Scholar
• Lipton R, Buse D, Serrano D, et al. Defining the border-zone between episodic migraine (EM) and chronic migraine (CM): sociodemographics and headache-related disability in the US population. Neurology. 2013;80(MeetingAbstracts 1):P03.105.
   Google Scholar
• Serrano D, Buse D, Reed M, et al. Defining the border-zone between episodic migraine (EM) and chronic migraine (CM): medical comorbidities in the US population. Neurology. 2013;80(MeetingAbstracts 1):P03.110.
   Google Scholar
• Buse D, Serrano D, Reed M, et al. Defining the border-zone between episodic migraine (EM) and chronic migraine (CM): psychiatric comorbidities and chronic pain in the US population. Neurology. 2013;80(MeetingAbstracts 1):P03.109.
   Google Scholar
• Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55:3–20.
   PubMed Web of Science ®Google Scholar
• Silberstein SD Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55:754–762.
   PubMed Web of Science ®Google Scholar
• Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol. 2002;59:1084–1088.
   PubMed Web of Science ®Google Scholar
• Derry CJ, Derry S, Moore RA. Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012;2:CD009663.
   PubMed Web of Science ®Google Scholar
• Derry CJ, Derry S, Moore RA. Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012;2:CD009665.
   PubMed Web of Science ®Google Scholar
• Derry CJ, Derry S, Moore RA. Sumatriptan (rectal route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012;2:CD009664.
   Web of Science ®Google Scholar
• Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012;2:CD008615.
   PubMed Web of Science ®Google Scholar
• Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults – overview of Cochrane reviews. Cochrane Database Syst Rev. 2014;5:CD009108.
   PubMed Web of Science ®Google Scholar
• Bird S, Derry S, Moore RA. Zolmitriptan for acute migraine attacks in adults. Cochrane Database Syst Rev. 2014;5:CD008616.
   PubMedGoogle Scholar
• Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache. 2003;43:144–166.
   PubMed Web of Science ®Google Scholar
• Diener HC, Charles A, Goadsby PJ, et al. New therapeutic approaches for the prevention and treatment of migraine. Lancet Neurol. 2015;14:1010–1022.
   PubMed Web of Science ®Google Scholar
• Giamberardino MA, Martelletti P. Emerging drugs for migraine treatment. Expert Opin Emerg Drugs. 2015;20:137–147.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337–1345. Erratum: Neurology 2013;80:871.
   PubMed Web of Science ®Google Scholar
• Holland S, Silberstein SD, Freitag F, et al. NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1346–1353.
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Preventive migraine treatment. Continuum (Minneap Minn). 2015;21:973–989.
   PubMedGoogle Scholar
• Prescribing Focus: Optimizing migraine prevention therapy. [cited 2016 Feb 18]. Available from: https://hcp-prod.optumrx.com/vgnlive/HCP/Assets/PDF/PrescribingFocus_OptimizingMigrainePreventionTherapy_022011.pdf
   Google Scholar
• Starling AJ, Dodick DW. Best practices for patients with chronic migraine: burden, diagnosis, and management in primary care. Mayo Clin Proc. 2015;90:408–414.
   PubMed Web of Science ®Google Scholar
• Schwedt TJ. Chronic migraine. BMJ. 2014;348:g1416.
   PubMed Web of Science ®Google Scholar
• Giamberardino MA, Mitsikostas DD, Martelletti P. Update on medication-overuse headache and its treatment. Curr Treat Options Neurol. 2015;17:368.
   PubMed Web of Science ®Google Scholar
• BOTOX (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use. Prescribing information; 2016 [cited 2016 Feb 15]. Available from: http://www.allergan.com/assets/pdf/botox_pi.pdf
   Google Scholar
• Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015;55(S2):103–122.
   PubMed Web of Science ®Google Scholar
• Worthington I. Delivery systems for acute migraine medications. Can Fam Physician. 2001;47:322–329.
   PubMed Web of Science ®Google Scholar
• Parkman HP. Migraine and gastroparesis from a gastroenterologist’s perspective. Headache. 2013;53(Suppl. 1):4–10.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Marcus DA. Sumatriptan: treatment across the full spectrum of migraine. Expert Opin Pharmacother. 2013;14:1659–1667.
   PubMed Web of Science ®Google Scholar
• Imitrex (sumatriptan nasal spray). Prescribing information; 2013 [cited 2015 Jun 13]. Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Imitrex_Nasal_Spray/pdf/IMITREX-NASAL-SPRAY-PI-PIL.PDF
   Google Scholar
• Ryan R, Elkind A, Baker CC, et al. Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies. Neurology. 1997;49:1225–1230.
   PubMed Web of Science ®Google Scholar
• Diamond S, Elkind A, Jackson RT, et al. Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine. Arch Fam Med. 1998;7:234–240.
   PubMedGoogle Scholar
• IMITREX (sumatriptan succinate) injection, for subcutaneous use; Prescribing information; 2015 [cited 2015 Jun 13]. Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Imitrex_Injection/pdf/IMITREX-INJECTION-PI-PPI-PIL-COMBINED.PDF
   Google Scholar
• Goldstein J, Smith TR, Pugach N, et al. A sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Headache. 2012;52:1402–1410.
   PubMed Web of Science ®Google Scholar
• Zecuity (sumatriptan iontophoretic transdermal system). Prescribing information; 2014 [cited 2015 Jun 13]. Available from: http://www.zecuity.com/PDF/ZECUITY_PI.pdf
   Google Scholar
• Smith TR, Goldstein J, Singer R, et al. Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system. Headache. 2012;52:612–624.
   PubMed Web of Science ®Google Scholar
• Charlesworth BR, Dowson AJ, Purdy A, et al. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs. 2003;17:653–667.
   PubMed Web of Science ®Google Scholar
• Dodick D, Brandes J, Elkind A, et al. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study. CNS Drugs. 2005;19:125–136.
   PubMed Web of Science ®Google Scholar
• Gawel M, Aschoff J, May A, et al. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine–results from phase 1 of the REALIZE study. Headache. 2005;45:7–16.
   PubMed Web of Science ®Google Scholar
• ZOMIG (zolmitriptan) nasal spray. Prescribing information; 2013 [cited 2015 Jun 13]. Available from: http://www1.astrazeneca-us.com/pi/zomignasalspray.pdf
   Google Scholar
• Migranal® (dihydroergotamine mesylate, USP). Prescribing information; 2007 [cited 2015 Jun 13]. Available from: http://valeant.com/Portals/25/Pdf/PI/Migranal-PI.pdf
   Google Scholar
• Schürks M. Dihydroergotamine: role in the treatment of migraine. Expert Opin Drug Metab Toxicol. 2009;5:1141–1148.
   PubMed Web of Science ®Google Scholar
• Aurora SK, Rozen TD, Kori SH, et al. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Headache. 2009;49:826–837.
   PubMed Web of Science ®Google Scholar
• Aurora SK, Silberstein SD, Kori SH, et al. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache. 2011;51:507–517.
   PubMed Web of Science ®Google Scholar
• Noveck RJ, Douglas PS, Chow SC, et al. Assessing acute systemic effects of an inhaled drug with serial echocardiography: a placebo-controlled comparison of inhaled and intravenous dihydroergotamine. Drug Des Devel Ther. 2013;7:619–625.
   PubMed Web of Science ®Google Scholar
• Kellerman D, Kori S, Forst A, et al. Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans. Cephalalgia. 2012;32:150–158.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Kori SH. Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine. CNS Drugs. 2013;27:385–394.
   PubMed Web of Science ®Google Scholar
• Edwards KR, Norton J, Behnke M. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. Headache. 2001;41:976–980.
   PubMed Web of Science ®Google Scholar
• Hoffert MJ, Couch JR, Diamond S, et al. Transnasal butorphanol in the treatment of acute migraine. Headache. 1995;35:65–69.
   PubMed Web of Science ®Google Scholar
• Stadol NS® (butorphanol tartrate) Nasal Spray. Prescribing information; 2002 [cited 2015 Jun 13]. Available from: http://www.drugs.com/pro/stadol.html
   Google Scholar
• Rothrock JF, Cady RK, Aurora SK, et al. Needle-free subcutaneous sumatriptan for triptan users requiring a change in migraine therapy: efficacy and impact on patient-rated functionality, satisfaction, and confidence. Curr Med Res Opin. 2011;27:2185–2191.
   PubMed Web of Science ®Google Scholar
• de Tommaso M, Sardaro M, Serpino C, et al. Fibromyalgia comorbidity in primary headaches. Cephalalgia. 2009;29:453–464.
   PubMed Web of Science ®Google Scholar
• de Tommaso M, Sciruicchio V. Migraine and central sensitization: clinical features, main comorbidities and therapeutic perspectives. Curr Rheumatol Rev. 2015 Dec 30. [Epub ahead of print].
   Google Scholar
• Tepper D. Pregnancy and lactation–migraine management. Headache. 2015;55:607–608.
   PubMedGoogle Scholar
• Dodick D, Lipton RB, Martin V, et al. Triptan Cardiovascular Safety Expert Panel. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004;44:414–425.
   PubMed Web of Science ®Google Scholar
• Tana C, Tafuri E, Tana M, et al. New insights into the cardiovascular risk of migraine and the role of white matter hyperintensities: is gold all that glitters? J Headache Pain. 2013;14:9.
   PubMed Web of Science ®Google Scholar